Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cytokine Release Syndrome × talquetamab × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 29 Recurrence 4 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Leukemia, Plasma Cell 1 Infections 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1 Cytokine Release Syndrome 1

Interventions

siltuximab 3 tocilizumab 1 talquetamab 1 Dexamethasone 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡